Part 6 · Chapter 6.5
Secretory Mechanisms
Epithelial fluid secretion relies primarily on Cl- efflux via apical CFTR or Ca2+-activated Cl- channels, driving paracellular Na+and osmotic H2O to follow. This chapter covers the CFTR pathway, cystic fibrosis, and cholera as pathological activation.
1. Cl- Secretion Pathway
Basolateral NKCC1 brings Cl- into the cell (driven by Na-K ATPase gradient). Apical CFTR (cAMP-activated) or CaCC (Ca-activated, TMEM16A) opens to release Cl- into the lumen. Lumen-negative voltage drives Na+through paracellular pathway; osmotic gradient drives H2O through paracellular + aquaporins. Net: isotonic fluid secretion.
2. CFTR & Cystic Fibrosis
CFTR (Cystic Fibrosis Transmembrane conductance Regulator) is an ABC-family Cl- channel gated by cAMP-PKA phosphorylation + ATP. ΔF508 in the first nucleotide-binding domain causes misfolding and ER retention, producing CF. Thick, dehydrated mucus obstructs airways, pancreatic ducts, bile ducts, and vas deferens. Corrector/potentiator drugs (VX-809/lumacaftor, VX-770/ivacaftor, and the triple combo Trikafta) have transformed CF prognosis — median survival now >50 yr vs. <20 yr in the 1970s.
Simulation: Cholera Pathology
Click Run to execute the Python code
Code will be executed with Python 3 on the server
3. Cholera
Vibrio cholerae produces cholera toxin, whose A1 subunit enters enterocytes and ADP-ribosylates Gsα at Arg201, locking it in the active GTP-bound state. Persistent adenylyl-cyclase activity raises cAMP 10–100×, opens CFTR constitutively, producing massive Cl--driven isotonic secretion (up to 20 L/day fluid loss). Mortality untreated ~50%; oral rehydration (M6.2) bypasses CFTR failure by using SGLT1, reducing mortality to <1%.
4. Salivary, Pancreatic, Gastric Secretion
Salivary acinar cells secrete Cl--driven isotonic primary saliva; ductal cells modify by Na+ reabsorption and HCO3-secretion. Pancreatic acinar cells secrete enzyme-rich primary fluid; ductal cells add HCO3- via CFTR + SLC26A6 antiporter. Gastric parietal cells secrete HCl via H+/K+ ATPase; proton-pump inhibitors (omeprazole) target this pump.
Key References
• Riordan, J. R. et al. (1989). “Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.” Science, 245, 1066–1073.
• Middleton, P. G. et al. (2019). “Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele.” N. Engl. J. Med., 381, 1809–1819.
• Harvey, R. A. & Ferrier, D. R. (2011). Biochemistry, 5th ed. Lippincott.